Relmada Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Relmada Therapeutics has a total shareholder equity of $72.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $84.4M and $12.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$83.61m |
Equity | US$72.05m |
Total liabilities | US$12.36m |
Total assets | US$84.41m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 4E2's short term assets ($84.4M) exceed its short term liabilities ($12.4M).
Long Term Liabilities: 4E2 has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 4E2 is debt free.
Reducing Debt: 4E2 has no debt compared to 5 years ago when its debt to equity ratio was 6.1%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4E2 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4E2 has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 36.3% each year.